Kadcyla Not Better Than Standard of Care as First Treatment for Advanced-Stage, HER2-Positive Disease, but Causes Fewer Side Effects January 23, 2017 | Leave a comment | Kadcyla Not Better Than Standard of Care as First Treatment for Advanced-Stage, HER2-Positive Disease, but Causes Fewer Side EffectsSource: BreastCancer.orgPublished on Monday, January 23, 2017
